Daniel Chang
Clinical Trials
- Recruiting Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
- Not Recruiting PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
- Recruiting Imaging and Biomarkers of Hypoxia in Solid Tumors
- Not Recruiting Combination SBRT (Stereotactic Body Radiotherapy) With TACE (Transarterial Chemoembolization) for Unresectable Hepatocellular Carcinoma
- Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
- Not Recruiting Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
- Not Recruiting Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
- Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
- Recruiting Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
- Recruiting Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
- Recruiting Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
- Not Recruiting Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
- Not Recruiting Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
- Not Recruiting S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
- Recruiting Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
Help
Trial Administration